Extended Research Article
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
Helena Earl
,
Louise Hiller
,
Anne-Laure Vallier
,
Shrushma Loi
,
Karen McAdam
,
Luke Hughes-Davies
et al.
-
Journal:
Health Technology Assessment Volume: 24, Issue: 40
-
Published:
2 September 2020